All In Biotech

Drug Trial Radar · NCT07148414

A Study of SPY072 in Rheumatic Disease

Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

285

Planned (sponsor's estimate)

Start

Aug 21, 2025

Primary completion

Oct 31, 2026

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Spyre Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).

Conditions

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Rheumatic Diseases
  • Rheumatic Joint Disease
  • PsA (Psoriatic Arthritis)
  • AxSpA
  • Rheumatologic Disease

Interventions

  • SPY002-072Drug

    Experimental

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)Time frame: Week 12
  2. Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)Time frame: Week 16
  3. Psoriatic Arthritis: Proportion of participants who achieve an American College of Rheumatology 20 Response Criteria (ACR20) responseTime frame: Week 16

Locations

64 sites in 8 countries. Site status is shown where the registry gives one.

  • Site 113

    Avondale, Arizona

  • Site 118

    Tucson, Arizona

  • Site 114

    Chula Vista, California

  • Site 111

    Covina, California

  • Site 108

    Tujunga, California

  • Site 112

    Upland, California

  • Site 107

    Whittier, California

  • Site 115

    Aventura, Florida

  • Site 109

    Hialeah, Florida

  • Site 106

    Ormond Beach, Florida

  • Site 110

    Tampa, Florida

  • Site 116

    Willowbrook, Illinois

  • Site 119

    Rockville, Maryland

  • Site 104

    Duncansville, Pennsylvania

  • Site 105

    Corpus Christi, Texas

  • Site 120

    Irving, Texas

  • Site 103

    Tomball, Texas

  • Site 102

    Tomball, Texas

  • Site 503

    Lovech, Lovech, Bulgaria

  • Site 502

    Pleven, Pleven, Bulgaria

  • Site 506

    Plovdiv, Plovdiv, Bulgaria

  • Site 505

    Plovdiv, Plovdiv, Bulgaria

  • Site 504

    Varna, Varna, Bulgaria

  • Site 706

    Hlučín, Hlučín, Czechia

  • Site 702

    Moravská Ostrava, Ostrava-město, Czechia

  • Site 704

    Pardubice, Pardubice Region, Czechia

  • Site 705

    Prague, Praha, Hlavní Mesto, Czechia

  • Site 703

    Prague, Praha, Hlavní Mesto, Czechia

  • Site 701

    Uherské Hradiště, Zlín, Czechia

  • Site 308

    Batumi, Georgia

  • Site 302

    Kutaisi, Georgia

  • Site 306

    Tbilisi, Georgia

  • Site 303

    Tbilisi, K'alak'i T'bilisi, Georgia

  • Site 304

    Tbilisi, K'alak'i T'bilisi, Georgia

  • Site 301

    Tbilisi, K'alak'i T'bilisi, Georgia

  • Site 307

    Tbilisi, K'alak'i T'bilisi, Georgia

  • Site 305

    Tbilisi, K'alak'i T'bilisi, Georgia

  • Site 201

    Chisinau, Moldova

  • Site 202

    Chisinau, Moldova

  • Site 401

    Krakow, Lesser Poland Voivodeship, Poland

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.